5 results on '"Pavletic, Steven Z."'
Search Results
2. Additional file 1 of Collection of peripheral blood mononucleated cells for chronic graft-versus-host disease immunology research: safety and effectiveness of leukapheresis in 132 patients
- Author
-
Mina, Alain, Curtis, Lauren, West, Kamille, Yau, Yu Ying, Cowen, Edward W., Hakim, Frances, and Pavletic, Steven Z.
- Abstract
Supplementary Material 1
- Published
- 2022
- Full Text
- View/download PDF
3. Motor ability, function, and health-related quality of life as correlates of symptom burden in patients with sclerotic chronic graft-versus-host disease receiving imatinib mesylate
- Author
-
Rosenthal, Emily A, Ho, Pei-Shu, Joe, Galen O, Mitchell, Sandra A, Booher, Susan, Pavletic, Steven Z, Baird, Kristin, Cowen, Edward W, and Comis, Leora E
- Subjects
Adult ,Male ,Adolescent ,Health-related quality of life ,Clinical Trials and Supportive Activities ,Graft vs Host Disease ,Medical and Health Sciences ,Young Adult ,Clinical Research ,Humans ,Clinical Trials ,Oncology & Carcinogenesis ,Child ,Sclerosis ,Phase II as Topic ,Rehabilitation ,Psychology and Cognitive Sciences ,Middle Aged ,Chronic graft-versus-host disease ,Brain Disorders ,Physical Rehabilitation ,Good Health and Well Being ,Functional impairment ,Motor Skills ,Chronic Disease ,Allogeneic hematopoietic stem cell transplantation ,Quality of Life ,Imatinib Mesylate ,Symptom burden ,Female - Abstract
PurposeTo explore improvement in motor ability, function, health-related quality of life (HRQOL), and symptom severity in patients with sclerotic chronic graft-versus-host disease (ScGVHD) in response to treatment as well as the relationship among changes on such measures.MethodsThis study was a secondary analysis of data from 13 individuals with severe ScGVHD enrolled in a clinical trial evaluating the efficacy of imatinib mesylate (clinicaltrials.gov identifier: NCT00702689). Self-reported, clinician-reported, and performance-based indicators of motor ability, function, HRQOL, and symptom severity were assessed at baseline and 6months following the administration of imatinib mesylate.ResultsParticipants did not show statistically significant improvement on any measures over time. Approximately one-third of patients displayed clinically significant improvement on measures of motor ability (palmar pinch strength, dominant hand, 30.8%), functioning (Manual Ability Measure-36, 41.7%), HRQOL (Short Form 36 [SF-36] Mental Component Summary, 33.3%), and symptom severity (Lee Symptom Scale, 38.5%). Improvement in cGVHD symptom burden was correlated with improvement in function (Assessment of Motor and Process Skills [AMPS] and Disabilities of the Arm, Shoulder, and Hand [DASH] scores) and HRQOL (SF-36 Physical Component Summary scores).ConclusionsFindings suggest the potential utility of administering patient-reported and performance-based functional measures, such as the DASH and the AMPS, to patients with cGVHD. By understanding the functional consequences of ScGVHD, interdisciplinary teams of health care providers, including rehabilitation professionals, can work to improve long-term outcomes.
- Published
- 2020
4. Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation
- Author
-
Ankit J, Kansagra, Noelle V, Frey, Merav, Bar, Theodore W, Laetsch, Paul A, Carpenter, Bipin N, Savani, Helen E, Heslop, Catherine M, Bollard, Krishna V, Komanduri, Dennis A, Gastineau, Christian, Chabannon, Miguel A, Perales, Michael, Hudecek, Mahmoud, Aljurf, Leslie, Andritsos, John A, Barrett, Veronika, Bachanova, Chiara, Bonini, Armin, Ghobadi, Saar I, Gill, Joshua, Hill, Saad, Kenderian, Partow, Kebriaei, Arnon, Nagler, David, Maloney, Hien D, Liu, Nirali N, Shah, Mohamed A, Kharfan-Dabaja, Elizabeth J, Shpall, Ghulam J, Mufti, Laura, Johnston, Elad, Jacoby, Ali, Bazarbachi, John F, DiPersio, Steven Z, Pavletic, David L, Porter, Stephan A, Grupp, Michel, Sadelain, Mark R, Litzow, Mohamad, Mohty, Shahrukh K, Hashmi, Kansagra, Ankit J., Frey, Noelle V., Bar, Merav, Laetsch, Theodore W., Carpenter, Paul A., Savani, Bipin N., Heslop, Helen E., Bollard, Catherine M., Komanduri, Krishna V., Gastineau, Dennis A., Chabannon, Christian, Perales, Miguel A., Hudecek, Michael, Aljurf, Mahmoud, Andritsos, Leslie, Barrett, John A., Bachanova, Veronika, Bonini, Chiara, Ghobadi, Armin, Gill, Saar I., Hill, Joshua, Kenderian, Saad, Kebriaei, Partow, Nagler, Arnon, Maloney, David, Liu, Hien D., Shah, Nirali N., Kharfan-Dabaja, Mohamed A., Shpall, Elizabeth J, Mufti, Ghulam J., Johnston, Laura, Jacoby, Elad, Bazarbachi, Ali, Dipersio, John F., Pavletic, Steven Z., Porter, David L., Grupp, Stephan A, Sadelain, Michel, Litzow, Mark R., Mohty, Mohamad, and Hashmi, Shahrukh K.
- Subjects
Pediatric Research Initiative ,Childhood Leukemia ,Pediatric Cancer ,Antigens, CD19 ,Adoptive ,Clinical Sciences ,Immunology ,Receptors, Antigen, T-Cell ,Practice Patterns ,Immunotherapy, Adoptive ,Article ,Young Adult ,Rare Diseases ,Medical ,Precursor B-Cell Lymphoblastic Leukemia-Lymphoma ,Receptors ,Genetics ,Humans ,Chimeric antigen receptor ,Practice Patterns, Physicians' ,Antigens ,Child ,Drug Approval ,Expert Testimony ,Societies, Medical ,Cancer ,Pediatric ,Transplantation ,Physicians' ,Leukemia ,CD19 ,5.2 Cellular and gene therapies ,T cell ,Gene Therapy ,Hematology ,T-Cell ,United States ,Orphan Drug ,Good Health and Well Being ,Antigen ,Critical Pathways ,Immunization ,Immunotherapy ,Development of treatments and therapeutic interventions ,Societies ,Biotechnology - Abstract
On August 30, 2017, the U.S. Food and Drug Administration (US-FDA) approved tisagenlecleucel (KYMRIAH, Novartis, Basel, Switzerland), a synthetic bioimmune product of anti-CD19 chimeric antigen receptor-T cells (CAR-T), for the treatment of children and young adults with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). With this new era of personalized cancer immunotherapy, multiple challenges are present ranging from implementation of a CAR-T program to safe delivery of the drug, long-term toxicity monitoring and disease assessments. To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL. This article presents an initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved.
- Published
- 2019
5. Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation
- Author
-
Claudio Anasetti, Miguel-Angel Perales, Emili Montserrat, Stephan Stilgenbauer, Christopher Bredeson, Edwin P. Alyea, Mehdi Hamadani, Jennifer R. Brown, Steven Z. Pavletic, Richard R. Furman, Bipin N. Savani, Susan O'Brien, Nishitha Reddy, Ambuj Kumar, John G. Gribben, Januario E. Castro, Peter Dreger, Mohamed L. Sorror, Mohamed A. Kharfan-Dabaja, Javier Pinilla-Ibarz, Jacqueline C. Barrientos, Mohamad Mohty, Brian T. Hill, Paolo Ghia, Carol Moreno, Farrukh T. Awan, Ernesto Ayala, Paul Carpenter, Kharfan Dabaja, Mohamed A., Kumar, Ambuj, Hamadani, Mehdi, Stilgenbauer, Stephan, Ghia, PAOLO PROSPERO, Anasetti, Claudio, Dreger, Peter, Montserrat, Emili, Perales, Miguel Angel, Alyea, Edwin P., Awan, Farrukh T., Ayala, Ernesto, Barrientos, Jacqueline C., Brown, Jennifer R., Castro, Januario E., Furman, Richard R., Gribben, John, Hill, Brian T., Mohty, Mohamad, Moreno, Carol, O'Brien, Susan, Pavletic, Steven Z., Pinilla Ibarz, Javier, Reddy, Nishitha M., Sorror, Mohamed, Bredeson, Christopher, Carpenter, Paul, and Savani, Bipin N.
- Subjects
Oncology ,medicine.medical_specialty ,Transplantation Conditioning ,Anthracycline ,medicine.medical_treatment ,Chronic lymphocytic leukemia ,B-cell receptor ,Antineoplastic Agents ,Article ,law.invention ,03 medical and health sciences ,0302 clinical medicine ,Randomized controlled trial ,immune system diseases ,law ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Humans ,Transplantation, Homologous ,Child ,Salvage Therapy ,BCR inhibitor ,Chemotherapy ,Transplantation ,business.industry ,Hematopoietic Stem Cell Transplantation ,breakpoint cluster region ,Hematology ,Allogeneic hematopoietic cell transplantation ,medicine.disease ,Leukemia, Lymphocytic, Chronic, B-Cell ,BCL-2 inhibitors ,Clinical trial ,BCR inhibitors ,Child, Preschool ,030220 oncology & carcinogenesis ,BCL-2 inhibitor ,Practice Guidelines as Topic ,Immunology ,business ,030215 immunology - Abstract
We sought to establish clinical practice recommendations to redefine the role of allogeneic hematopoietic cell transplantation (allo-HCT) for patients with chronic lymphocytic leukemia (CLL) in an era of highly active targeted therapies. We performed a systematic review to identify prospective randomized controlled trials comparing allo-HCT against novel therapies for treatment of CLL at various disease stages. In the absence of such data, we invited physicians with expertise in allo-HCT and/or CLL to participate in developing these recommendations. We followed the Grading of Recommendations Assessment, Development and Evaluation methodology. For standard-risk CLL we recommend allo-HCT in the absence of response or if there is evidence of disease progression after B cell receptor (BCR) inhibitors. For high-risk CLL an allo-HCT is recommended after failing 2 lines of therapy and showing an objective response to BCR inhibitors or to a clinical trial. It is also recommended for patients who fail to show an objective response or progress after BCR inhibitors and receive BCL-2 inhibitors, regardless of whether an objective response is achieved. For Richter transformation, we recommend allo-HCT upon demonstration of an objective response to anthracycline-based chemotherapy. A reduced-intensity conditioning regimen is recommended whenever indicated. These recommendations high-light the rapidly changing treatment landscape of CLL. Newer therapies have disrupted prior paradigms, and allo-HCT is now relegated to later stages of relapsed or refractory CLL. (C) 2016 American Society for Blood and Marrow Transplantation.
- Published
- 2016
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.